author-photo

Johanna C. Bendell

Sarah Cannon Research Institute
Duke University

621

Papers

13525

Citations

Citation Trend

Filter By

Papers (621) Sort By

Journal Conference Others

Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.

2021 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (1)
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.

2021 Journal of Immunotherapy
Show All
- Source
- Cite
- Save
Citations (1)
First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)